Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection
Key facts
- Who runs it
- Yongquan Shi
- Where
- China24 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 448 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 30 May 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Linalarose Glutarate
- Bismuth Quadruple Test
- Record updated
- 27 October 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- (1) Adult patients aged 18-70 years, regardless of gender
- (2) Patients diagnosed with Helicobacter pylori infection via 13C/14C-UBT
- (3) Patients who have not previously undergone Helicobacter pylori eradication therapy
- (4) Patients who have provided informed consent and voluntarily agreed to participate in this study
Who cannot take part
- (6) Patients with concomitant peptic ulcers, reflux esophagitis, MALT lymphoma, gastrointestinal malignancies, or those who have undergone esophageal or gastric surgery
- (9) Patients requiring treatment with atazanavir, nelfinavir, or rilpivirine
- (1) Individuals allergic to the study drug
- (4) Individuals with a history of failed Helicobacter pylori eradication therapy
- (7) Patients with severe cardiac, hepatic, pulmonary, or renal diseases, or those with impaired immunity
- (8) Patients unable to comply with treatment due to alcohol abuse, substance abuse, or severe mental illness
- (2) Individuals who have taken antibiotics, bismuth-containing agents, probiotics, or traditional Chinese medicines with antibacterial activity within the past 4 weeks
- (3) Individuals who have taken P-CAB, PPI, or H2 receptor antagonists within the past 2 weeks
- (5) Women who are pregnant, breastfeeding, or planning to become pregnant
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to compare the efficacy of the dual therapy regimen of linralase glutarate capsules and amoxicillin versus the quadruple therapy regimen containing bismuth for the first-line eradication of Helicobacter pylori infection. The primary questions this trial aims to address include: 1. Whether the linalarenate glutarate capsule-amoxicillin dual-drug regimen is non-inferior to the bismuth-containing quadruple therapy, while simultaneously evaluating patient adherence and the incidence of adverse events in both treatment groups. Participants will: 1. Treatment group: Linaralate Glutarate Capsules (50 mg bid) + Amoxicillin (1 g tid), for a 14-day treatment course. 2. Control group: Esomeprazole 20 mg, twice daily (bid) + clarithromycin 0.5 g, twice daily (bid) + amoxicillin 1 g, twice daily (bid) + colloidal bismuth subcitrate 200 mg, twice daily (bid), for a 14-day treatment course. The primary endpoint is the Helicobacter pylori eradication rate 4 weeks after discontinuation of treatment.
The 2 groups in the trial
- Treatment groupTreatment being tested
Glutaric acid linalaric acid ester capsules (50 mg bid) + amoxicillin (1 g tid), for a 14-day course.
Treatment: Linalarose Glutarate
- Control groupExisting treatment, for comparison
Esomeprazole 20 mg, twice daily (bid) + clarithromycin 0.5 g, twice daily (bid) + amoxicillin 1 g, twice daily (bid) + colloidal bismuth subcitrate 200 mg, twice daily (bid), for a 14-day treatment course.
Treatment: Bismuth Quadruple Test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Controlled Study
- Criteria questions
- Built from NCT07897994, who can take part
- Record updated
- 27 October 2026